Discovery and characterization of potential drivers of resistance to the KRAS G12D inhibitor, MRTX1133, in cancer cell line models

被引：0
|
作者：
Helu, Xousaen M.
Griffiths, Ellie
Calinisan, Andrew
Hebbert, Allan
Yan, Larry
Hoffman, Natalie
Trinh, David
Hover, Laura
Fernandez-Banet, Julio
Briere, David M.
Lifset, Ella
Olson, Peter
Christensen, James G.
Hallin, Jill
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-1943
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1943
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Strategies to improve KRAS G12D inhibitor (MRTX1133) therapy in pancreatic ductal adenocarcinoma
    Gulay, Kevin Christian M.
    Esparza, Edgar
    Zhang, Xinlian
    Mose, Evangeline S.
    Weitz, Jonathan
    Pu, Minya
    Messer, Karen
    Lowy, Andrew M.
    Tiriac, Herve
    CANCER RESEARCH, 2022, 82 (22) : 50 - 50
  • [2] A non-conserved histidine residue on KRAS drives paralog selectivity of the KRAS G12D inhibitor MRTX1133
    Keats, Miles
    Han, John
    Lee, Yeon-Hwa
    Lee, Chih-Shia
    Luo, Ji
    MOLECULAR CANCER RESEARCH, 2023, 21 (05)
  • [3] Activity of the KRAS G12D Inhibitor MRTX1133 against the Mutant KRAS Triple-Negative MDA-MB-231 Breast Cancer Cell Line
    Teufelsbauer, Maryana
    Stickler, Sandra
    Eggerstorfer, Marie-Therese
    Weigl, Lukas
    Hamilton, Gerhard
    JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 2024, 38 (03): : 1933 - 1942
  • [4] Pathways and mechanism of MRTX1133 binding to KRAS G12D elucidated by molecular dynamics simulations and Markov state models
    Tu, Gao
    Gong, Yaguo
    Yao, Xiaojun
    Liu, Qing
    Xue, Weiwei
    Zhang, Rong
    INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2024, 274
  • [5] Characterization of the binding of MRTX1133 as an avenue for the discovery of potential KRASG12D inhibitors for cancer therapy
    Abdul Rashid Issahaku
    Namutula Mukelabai
    Clement Agoni
    Mithun Rudrapal
    Sahar M. Aldosari
    Sami G. Almalki
    Johra Khan
    Scientific Reports, 12
  • [6] The KRASG12D inhibitor MRTX1133 elucidates KRAS-mediated oncogenesis
    Christensen, James G.
    Hallin, Jill
    NATURE MEDICINE, 2022, 28 (10) : 2017 - 2018
  • [7] The KRASG12D inhibitor MRTX1133 elucidates KRAS-mediated oncogenesis
    Nature Medicine, 2022, 28 : 2017 - 2018
  • [8] Characterization of the binding of MRTX1133 as an avenue for the discovery of potential KRASG12D inhibitors for cancer therapy
    Issahaku, Abdul Rashid
    Mukelabai, Namutula
    Agoni, Clement
    Rudrapal, Mithun
    Aldosari, Sahar M.
    Almalki, Sami G.
    Khan, Johra
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [9] Co-treatment with KRAS G12D inhibitor MRTX1133 plus TTFields against human pancreatic and Colorectal cancer cell lines results in synergistic up-regulation of cleaved PARP in KRAS G12D & unexpectedly in KRAS G12V as well
    Tajiknia, Vida
    Srinivasan, Praveen
    PInho-Schwermann, Maximilian
    MacDonald, William
    Purcell, Connor
    El-Deiry, Wafik
    CANCER RESEARCH, 2024, 84 (06)
  • [10] Combination of 5-FU plus KRAS G12D inhibitor MRTX1133 against human colorectal and pancreatic cancer cells and the affects on inhibition of pERK and immune-stimulatory cytokine patterns in in KRAS G12D and KRAS G12V tumor cells
    Tajiknia, Vida
    El-Deiry, Wafik S.
    Schwermann, Maximilian
    Huntington, Kelsey
    Zhou, Lanlan
    Srinivasan, Praveen
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345